Norges Bank’s Tonix Pharmaceuticals TNXP Stock Holding History

Norges Bank’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4	Closed	-$3.06M	–	2345
2021 Q2	$3.06M	Buy	+4	New	+$2.94M	﹤0.01%	1963

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank's TNXP Position: Q3 2021 in Review

Norges Bank sold out of Tonix Pharmaceuticals (TNXP) in Q3 2021, closing a stake of 4 shares — an estimated $3.06M sold.

Norges Bank first reported a position in TNXP in Q2 2021 and held it in 1 quarter. The position peaked at $3.06M in Q2 2021. 18 funds tracked by Wall St. Rank hold TNXP as of Q3 2021.

Norges Bank reported no remaining Tonix Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Norges Bank sold 4 Tonix Pharmaceuticals shares in Q3 2021, an estimated $3.06M.
Norges Bank first reported a position in Tonix Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Norges Bank's Tonix Pharmaceuticals position peaked at $3.06M in Q2 2021.
18 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2021.

Based on Norges Bank's 13F filing for Q3 2021, filed 5 Nov 2021.